SciELO - Scientific Electronic Library Online

 
vol.30 número3Asociación de polimorfismos de IL-1β +3954 G>A e IL-6-174 G/C en la toxoplasmosis congénitaVacunas contra la COVID-19: desarrollo, estrategias, tipos y reticencia al uso de la vacunación índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

  • No hay articulos citadosCitado por SciELO

Links relacionados

  • No hay articulos similaresSimilares en SciELO

Compartir


Vaccimonitor

versión impresa ISSN 1025-028Xversión On-line ISSN 1025-0298

Resumen

LIMA-PEREZ, Mayté et al. Nimotuzumab combined with GEMOX chemotherapy regimen in patients with advanced pancreatic cancer. Vaccimonitor [online]. 2021, vol.30, n.3, pp.133-144.  Epub 01-Dic-2021. ISSN 1025-028X.

A retrospective and observational study was carried out in patients with advanced pancreatic adenocarcinoma, treated with Nimotuzumab combined with a GEMOX chemotherapy scheme, in the Clinical Oncology Service at the Ameijeiras Hospital, between 2013 and 2019 (n =118), whose objective was to evaluate the response to the treatment and overall survival according to clinical, histopathological and treatment variables. The chi-square method was used for the association of variables. Overall survival was evaluated by the Kaplan Meier method and the Log-Rank and Breslow test for the comparison of the curves, with p <0.05. The disease control rate was 44.9. The median survival was 13.8 months (95% CI: 11.7-15.8). The statistically significant variables associated with greater response to treatment and survival were: no smoking habits; platelet-lymphocyte index below 200; T2-T3 primary tumors, predominantly located in the pancreatic head; no presence of metastases at diagnosis and greater than six doses of chemotherapy and Nimotuzumab. Patients classified as underweight and low serum albumin had worse survival (p <0.05). Second-line chemotherapy was performed in 42 patients and it was obtained SV of 17.4 months (95% CI: 13.5-21.4). Toxicities classified as grade 3-4 were reported in 27 patients (22.9%); the most frequently observed were: neuropathy (14.4%), neutropenia (10.2%) and thrombopenia (9.3%). Under clinical practice conditions, Nimotuzumab combined with GEMOX chemotherapy obtained optimal disease control and survival rates with a good safety profile.

Palabras clave : Nimotuzumab; pancreatic cancer; drug therapy; survival analysis.

        · resumen en Español     · texto en Español     · Español ( pdf )